In the gaslit streets of Victorian London, where medicine was as much art as science, a peculiar affliction began whispering its secrets to the world. It was the late 19th century, and Sir Jonathan Hutchinson—a brilliant surgeon, dermatologist, and polymath at King’s College Hospital—first encountered patients with strange, purplish plaques blooming across their faces and hands. These weren’t ordinary rashes; they were raised, livid, and oddly symmetrical, like bruises from some invisible assailant. Hutchinson, ever the keen observer (he had already cataloged everything from syphilis to teeth anomalies), dubbed one famous case “Mortimer’s malady” after his patient, Mrs. Mortimer, whose disfiguring lesions defied easy explanation. He suspected sarcoma—a fleshy cancer—but biopsies hinted at something far more enigmatic: benign yet persistent nodules of inflamed tissue. Little did he know, he had just documented the first known case of what would become one of medicine’s most baffling riddles: sarcoidosis.20

Fast-forward to 1899 in snowy Christiania (now Oslo), Norway. Enter Caesar Boeck, a sharp-eyed dermatologist whose uncle, Carl Boeck, had also dabbled in skin mysteries. Boeck examined a patient with similar eruptions—small, tumor-like lumps scattered across the skin—and coined a name that perfectly captured their eerie quality: multiple benign sarkoid of the skin. The term “sarkoid” came straight from the Greek: sark for “flesh” and -oid for “like,” evoking something that mimicked the raw, meaty texture of a sarcoma but was, crucially, not malignant. It was a “fleshy tumor” in appearance only—benign, yet insistent. Boeck’s detailed report, complete with histological sketches of epithelioid cells and giant cells forming non-caseating granulomas, turned heads across Europe. What had seemed like isolated skin curiosities now had a label, but its true nature remained veiled.15

By the early 1900s, the plot thickened into a medical whodunit. European physicians, peering through microscopes at these granulomas, couldn’t shake the resemblance to tuberculosis—the great imitator of the era. Sarcoidosis looked like a “forme fruste” of TB: a stealthy, incomplete version of the bacterial scourge, with its telltale nodules but without the cheesy caseation necrosis or positive sputum tests. Was it an atypical mycobacterial infection? A cousin of consumption? The debate raged in journals and congresses. French dermatologist Ernest Besnier had already described “lupus pernio”—those frostbitten-looking purple plaques on noses and ears—in 1889, adding frost to the fire. Yet autopsies and cultures kept coming up empty for live bacilli. The disease teased doctors: it acted infectious but refused to confess its culprit.21

The 1910s and 1920s brought the great reveal. Pioneers like Jörgen Schaumann in Sweden pieced together the puzzle: this wasn’t just a skin disease. It infiltrated lungs, lymph nodes, eyes, bones, spleen, and nerves— a systemic shapeshifter causing everything from breathlessness to uveitis to “uveoparotid fever” (as described by Danish ophthalmologist Christian Heerfordt). By the 1930s, the consensus crystallized: sarcoidosis was no mere dermatological oddity but a multisystem granulomatous disorder, striking rich and poor alike, often in young adults. Radiologists marveled at the “potato nodes” of bilateral hilar lymphadenopathy on chest X-rays; pathologists marveled at the “naked” granulomas devoid of surrounding inflammation. Yet the cause? Still a ghost.

Then came the eureka moment in 1941, courtesy of another Norwegian visionary, dermatologist Morten Ansgar Kveim. Working with sarcoid patients, Kveim made a daring observation: if you took sterilized suspension from a sarcoid patient’s lymph node or spleen and injected it intradermally into another sarcoid sufferer, a tiny granuloma would form at the site weeks later—replicating the disease’s signature lesion. Healthy people? No reaction. TB patients? Usually nothing. This “Kveim test” (later refined by Louis Siltzbach) was revolutionary. It didn’t just diagnose; it proved sarcoidosis was an immune-mediated hypersensitivity reaction, a rogue allergic response to some hidden antigen lurking in the very tissue. For the first time, the disease turned on itself in a controlled experiment, like a detective using the criminal’s own fingerprint. The test became a global gold standard for decades, a quirky yet elegant tool in an era before CT scans and biopsies ruled the day.0

Yet the ultimate twist endures to this day: the antigen remains maddeningly elusive. What triggers the granulomatous frenzy? Kveim’s reagent worked like a charm, but its secret ingredient? Never isolated. Modern sleuths have turned to molecular forensics. PCR studies have repeatedly unearthed fragments of mycobacterial DNA—echoes of Mycobacterium tuberculosis or nontuberculous species—in sarcoid tissues, far more often than in controls. Are these ghostly remnants of a long-gone infection, persisting as molecular fossils that spark an autoimmune-like storm in genetically susceptible hosts? Or is it a red herring, with propionibacteria or environmental antigens also in the mix? The debate simmers in labs worldwide, as sarcoidosis continues to defy vaccines, cures, or even a single smoking-gun cause. It affects millions, often silently progressing to fibrosis in lungs or heart, yet many cases burn out spontaneously—like a fire that lights itself and extinguishes without explanation.

From Hutchinson’s purple plaques in foggy London to Boeck’s fleshy christening in Nordic labs, through TB shadows and Kveim’s injection alchemy, sarcoidosis remains medicine’s ultimate unsolved mystery: a disease that mimics cancer, infection, and autoimmunity but is none of them fully. It reminds us that some stories in science don’t end with neat revelations—they evolve, intrigue, and invite the next generation of detectives to keep hunting. Who knows what the next biopsy or genome scan will uncover? The flesh-like enigma endures, as alive today as those first plaques over 150 years ago.